Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

41. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Multiple sclerosis Last reviewed: August 2018 Last updated: May 2018 Important updates MS drug daclizumab withdrawn worldwide because of safety concerns Daclizumab, an immunomodulatory drug used in the treatment of relapsing forms of multiple sclerosis, has been removed from the worldwide market due to mounting concerns over its (...) events being reported, characterising the evolving benefit/risk profile of daclizumab will not be possible going forward given the limited number of patients being treated.” 2017 revisions to the McDonald diagnostic criteria for multiple sclerosis The 2017 McDonald criteria include the following changes: In patients with a typical clinically isolated syndrome and clinical or MRI demonstration of dissemination in space, the presence of CSF-specific oligoclonal bands allows a diagnosis

BMJ Best Practice2018

45. PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage European Medicines Agency - News and Events - PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage Search for medicines Main navigation News and press releases PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage Press release 27/10/2017 PRAC recommends further (...) restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage Zinbryta to be used only in a restricted patient group, with strict liver monitoring EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) is recommending further restrictions on the use of the multiple sclerosis medicine Zinbryta (daclizumab) following a review of the medicine’s effects on the liver. The review found that unpredictable and potentially fatal immune-mediated liver injury can occur during treatment

European Medicines Agency - EPARs2017

47. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality 28931645 2017 09 21 2017 10 24 2017 10 24 1526-632X 89 16 2017 Oct 17 Neurology Neurology Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. 1668-1675 10.1212/WNL.0000000000004508 To investigate the effect of chronic comorbidity on the time of diagnosis of multiple sclerosis (MS) and on mortality in MS. We conducted a population-based, nationwide cohort (...) study including all incident MS cases in Denmark with first MS symptom between 1980 and 2005. To investigate the time of diagnosis, we compared individuals with and without chronic comorbidity using multinomial logistic regression. To investigate mortality, we used Cox regression with time-dependent covariates, following study participants from clinical MS onset until endpoint (death) or to the end of the study, censuring at emigration. We identified 8,947 individuals with clinical onset of MS

EvidenceUpdates2017

48. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. BACKGROUND: Multiple sclerosis is a degenerative inflammatory disease of the CNS characterised by immune-mediated destruction of myelin and progressive neuroaxonal loss. Myelin in the CNS is a specialised extension of the oligodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyte precursor cells in vitro (...) , in animal models, and in human cells. We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple sclerosis. METHODS: We did this single-centre, 150-day, double-blind, randomised, placebo-controlled, crossover trial (ReBUILD) in patients with relapsing multiple sclerosis with chronic demyelinating optic neuropathy on stable immunomodulatory therapy. Patients who fulfilled international panel criteria for diagnosis with disease duration of less than 15

Lancet2017

49. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page (...) from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation {{author}} {{($index , , , , , , , , , , , , & . GJ Melendez-Torres 1, * , Peter Auguste 1 , Xavier Armoiry 1 , Hendramoorthy Maheswaran 1 , Rachel Court 1

NIHR HTA programme2017

50. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation Melendez-Torres G, Auguste P, Armoiry X, Maheswaran (...) -effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 2017; 21(52) Authors' objectives To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating

Health Technology Assessment (HTA) Database.2017

52. Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial

Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial 28629268 2017 06 20 2017 06 20 1477-0873 2017 Jun 01 Clinical rehabilitation Clin Rehabil Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial. 269215517714592 10.1177/0269215517714592 To evaluate the effect of Cawthorne-Cooksey and Frenkel exercises on balance (...) in patients with multiple sclerosis. It was a three-arm parallel randomized controlled trial study. Outpatient clinic. Patients with multiple sclerosis. Subjects in the intervention groups completed a 12-week program consisted of Cawthorne-Cooksey or Frenkel exercises. The control group only received routine care. The outcome measure was the Berg Balance Scale. Seventy-two patients completed the study. At the end of the intervention, there was a statistically significant improvement in Berg Balance Scale

EvidenceUpdates2017

53. Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment

Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Search Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients (...) and symptoms of hepatic injury. If there is evidence of hepatic injury (either clinically or laboratory), treatment should be stopped and the patient should be promptly referred to a hepatologist. Restrictions on use Treatment with daclizumab (Zinbryta▼) should now only be initiated in patients in the following restricted groups: highly active relapsing multiple sclerosis that has failed to respond to at least one disease-modifying therapy severe relapsing multiple sclerosis unsuitable for treatment

MHRA Drug Safety Update2017

54. Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)

Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) July 2017 Technology Description: The current treatment is already licensed in adults (...) , but is currently in a phase III trial for the treatment of multiple sclerosis in paediatric patients. Fingolimod will be administered orally once daily at a dose of either 0.5 mg or 0.25 mg depending on the patient’s body weight. If marketed this will become the first treatment with a specific licensed indication for paediatric multiple sclerosis. Specialty You may also be interested in: Apr 2015 Specialty: Apr 2015 Specialty: Apr 2015 Specialty: Please answer these 2 questions to proceed to your free download

NIHR Innovation Observatory2017

55. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial 28600189 2017 06 10 2017 06 10 1474-4465 2017 Jun 06 The Lancet. Neurology Lancet Neurol Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS (...) -STAT randomised, placebo-controlled trial. S1474-4422(17)30113-8 10.1016/S1474-4422(17)30113-8 In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures

EvidenceUpdates2017

56. Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression

Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression 28602542 2017 06 12 2017 06 12 1873-2607 2017 Jun 08 American journal of preventive medicine Am J Prev Med Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression. S0749-3797(17)30246-5 10.1016/j.amepre.2017.04.011 This study examined the extent to which patient and trial characteristics moderate the effects of exercise on depressive symptoms among people (...) with multiple sclerosis. Twenty-four effects were derived from 14 articles published before August 2016 located using Google Scholar, MEDLINE, PsycINFO, PubMed, and Web of Science. Trials involved 624 people with multiple sclerosis and included both randomization to exercise training or a non-exercise control condition and measurement of depressive symptoms at baseline and at mid- and/or post-intervention. Hedges' d effect sizes were computed, study quality was assessed, and random effects models were used for all

EvidenceUpdates2017

57. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]

[Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe

Health Technology Assessment (HTA) Database.2017

58. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. BACKGROUND: On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis. METHODS: During the period from January 2009 through July 2013, we randomly assigned participants who had had their first demyelinating symptoms (...) within the previous 180 days to receive either 100 mg of minocycline, administered orally twice daily, or placebo. Administration of minocycline or placebo was continued until a diagnosis of multiple sclerosis was established or until 24 months after randomization, whichever came first. The primary outcome was conversion to multiple sclerosis (diagnosed on the basis of the 2005 McDonald criteria) within 6 months after randomization. Secondary outcomes included conversion to multiple sclerosis within

NEJM2017

59. Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy

Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy - GOV.UK GOV.UK uses cookies to make the site simpler. Search Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy From: Published: 24 April 2017 Therapeutic area: Healthcare professionals should report any suspected adverse effects relating to fingolimod (Gilenya▼) or other (...) treatments for multiple sclerosis, including suspected adverse effects occurring after discontinuation, via the Yellow Card Scheme. We are aware of two recently published articles describing a suspected rebound syndrome (clinical and radiological signs of severe exacerbation beyond what was expected for that patient prior to discontinuation or treatment change) in patients with multiple sclerosis after treatment with fingolimod (Gilenya▼) was stopped, some of whom were switched to other treatments

MHRA Drug Safety Update2017

60. Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis

Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis Ocrevus (ocrelizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Ocrevus (ocrelizumab) Injection Ocrevus Company: Genentech, Inc. Application No.: 761053 Approval Date: 03/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2017